中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

文献类型：期刊论文

作者Li, Yuan1,2; Du, Yang3; Sun, Ting1,2; Xue, Huadan1,2; Jin, Zhengyu1,2; Tian, Jie3
刊名BMC CANCER
出版日期2018-06-19
卷号18页码:7
ISSN号1471-2407
关键词PD-1 Zoledronic acid Breast cancer Therapy Checkpoint inhibitior
DOI10.1186/s12885-018-4412-8
通讯作者Jin, Zhengyu(jin_zhengyu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
英文摘要Background: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. Methods: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. Results: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. Conclusion: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment.
WOS关键词CHECKPOINT INHIBITORS ; PHASE-3 TRIAL ; OPEN-LABEL ; METASTASES ; ANTIBODY ; THERAPY ; LIGAND ; SAFETY
资助项目National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81171390] ; Key Projects in the National Science & Technology Pillar Program[2012BAI23B06] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science & Technology Commission[Z161100002616022]
WOS研究方向Oncology
语种英语
出版者BIOMED CENTRAL LTD
WOS记录号WOS:000435892200004
资助机构National Natural Science Foundation of China ; Key Projects in the National Science & Technology Pillar Program ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science & Technology Commission
源URL[http://ir.ia.ac.cn/handle/173211/23180]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Jin, Zhengyu; Tian, Jie
作者单位1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
2.Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China
3.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, Key Lab Mol Imaging CAS, 95 ZhongGuanCun East Rd, Beijing 100190, Peoples R China
推荐引用方式
GB/T 7714		 Li, Yuan,Du, Yang,Sun, Ting,et al. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model[J]. BMC CANCER,2018,18:7.
APA Li, Yuan,Du, Yang,Sun, Ting,Xue, Huadan,Jin, Zhengyu,&Tian, Jie.(2018).PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.BMC CANCER,18,7.
MLA Li, Yuan,et al."PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model".BMC CANCER 18(2018):7.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。